These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 25409322)

  • 41. Speech in prodromal and symptomatic Huntington's disease as a model of measuring onset and progression in dominantly inherited neurodegenerative diseases.
    Chan JCS; Stout JC; Vogel AP
    Neurosci Biobehav Rev; 2019 Dec; 107():450-460. PubMed ID: 31419452
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.
    Tabrizi SJ; Scahill RI; Owen G; Durr A; Leavitt BR; Roos RA; Borowsky B; Landwehrmeyer B; Frost C; Johnson H; Craufurd D; Reilmann R; Stout JC; Langbehn DR;
    Lancet Neurol; 2013 Jul; 12(7):637-49. PubMed ID: 23664844
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Computerised Dynamic Posturography in Premanifest and Manifest individuals with Huntington's Disease.
    Reyes A; Salomonczyk D; Teo WP; Medina LD; Bartlett D; Pirogovsky-Turk E; Zaenker P; Bloom JC; Simmons RW; Ziman M; Gilbert PE; Cruickshank T
    Sci Rep; 2018 Oct; 8(1):14615. PubMed ID: 30279429
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Perceptual Detection of Subtle Dysphonic Traits in Individuals with Cervical Spinal Cord Injury Using an Audience Response Systems Approach.
    Johansson K; Strömbergsson S; Robieux C; McAllister A
    J Voice; 2017 Jan; 31(1):126.e7-126.e17. PubMed ID: 26850470
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dissociation between decision-making under risk and decision-making under ambiguity in premanifest and manifest Huntington's disease.
    Adjeroud N; Besnard J; Verny C; Prundean A; Scherer C; Gohier B; Bonneau D; Massioui NE; Allain P
    Neuropsychologia; 2017 Aug; 103():87-95. PubMed ID: 28712946
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Abnormal Electrophysiological Motor Responses in Huntington's Disease: Evidence of Premanifest Compensation.
    Turner LM; Croft RJ; Churchyard A; Looi JC; Apthorp D; Georgiou-Karistianis N
    PLoS One; 2015; 10(9):e0138563. PubMed ID: 26406226
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acoustic analysis of four common voice diagnoses: moving toward disorder-specific assessment.
    Gillespie AI; Dastolfo C; Magid N; Gartner-Schmidt J
    J Voice; 2014 Sep; 28(5):582-8. PubMed ID: 24880672
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acoustic analysis of voice in Huntington's disease patients.
    Velasco García MJ; Cobeta I; Martín G; Alonso-Navarro H; Jimenez-Jimenez FJ
    J Voice; 2011 Mar; 25(2):208-17. PubMed ID: 20137889
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Verbal communication disorders in psychogenic dysphonia.
    Kosztyła-Hojna B; Moskal-Jasińska D; Kraszewska A; Łobaczuk-Sitnik A; Zdrojkowski M; Duchnowska E; Biszewska J
    Otolaryngol Pol; 2019 Apr; 73(4):14-20. PubMed ID: 31474620
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-Time Voice Accumulation During Work, Leisure, and a Vocal Loading Task in Groups With Different Levels of Functional Voice Problems.
    Whitling S; Lyberg-Åhlander V; Rydell R
    J Voice; 2017 Mar; 31(2):246.e1-246.e10. PubMed ID: 27743846
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phonatory symptoms and impact on quality of life in female patients with goiter.
    Hamdan AL; Dowli A; Jabbour J; Sabri A; Azar ST
    Ear Nose Throat J; 2016 Jul; 95(7):E5-E10. PubMed ID: 27434485
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical and Biomarker Changes in Premanifest Huntington Disease Show Trial Feasibility: A Decade of the PREDICT-HD Study.
    Paulsen JS; Long JD; Johnson HJ; Aylward EH; Ross CA; Williams JK; Nance MA; Erwin CJ; Westervelt HJ; Harrington DL; Bockholt HJ; Zhang Y; McCusker EA; Chiu EM; Panegyres PK;
    Front Aging Neurosci; 2014; 6():78. PubMed ID: 24795630
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hepatic mitochondrial dysfunction in manifest and premanifest Huntington disease.
    Stüwe SH; Goetze O; Lukas C; Klotz P; Hoffmann R; Banasch M; Orth M; Schmidt WE; Gold R; Saft C
    Neurology; 2013 Feb; 80(8):743-6. PubMed ID: 23390182
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adductor spasmodic dysphonia and muscular tension dysphonia: acoustic analysis of sustained phonation and reading.
    Sapienza CM; Walton S; Murry T
    J Voice; 2000 Dec; 14(4):502-20. PubMed ID: 11130109
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adductor spastic dysphonia: heterogeneity of physiologic and phonatory characteristics.
    Davis PJ; Boone DR; Carroll RL; Darveniza P; Harrison GA
    Ann Otol Rhinol Laryngol; 1988; 97(2 Pt 1):179-85. PubMed ID: 3355046
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quantitative assessment of motor speech abnormalities in idiopathic rapid eye movement sleep behaviour disorder.
    Rusz J; Hlavnička J; Tykalová T; Bušková J; Ulmanová O; Růžička E; Šonka K
    Sleep Med; 2016 Mar; 19():141-7. PubMed ID: 26459688
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Symptom improvement of spastic dysphonia in response to phonatory tasks.
    Bloch CS; Hirano M; Gould WJ
    Ann Otol Rhinol Laryngol; 1985; 94(1 Pt 1):51-4. PubMed ID: 3970505
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Articulatory changes following treatment of muscle tension dysphonia: preliminary acoustic evidence.
    Dromey C; Nissen SL; Roy N; Merrill RM
    J Speech Lang Hear Res; 2008 Feb; 51(1):196-208. PubMed ID: 18230866
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Factors predicting patient perception of dysphonia caused by benign vocal fold lesions.
    Behrman A; Sulica L; He T
    Laryngoscope; 2004 Oct; 114(10):1693-700. PubMed ID: 15454756
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease.
    Russell DS; Barret O; Jennings DL; Friedman JH; Tamagnan GD; Thomae D; Alagille D; Morley TJ; Papin C; Papapetropoulos S; Waterhouse RN; Seibyl JP; Marek KL
    JAMA Neurol; 2014 Dec; 71(12):1520-8. PubMed ID: 25322077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.